Companies › Nanjing Immunophage Biotech
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IPG1094 Macrophage migration inhibitory factor (MIF) inhibitor | MIF | Phase 1 | Healthy Volunteers; Solid Tumor | Jan 2027 |
| IPG7236 | – | Phase 1 | Advanced Solid Tumor | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07679113 | IPG1094 | Phase 1 | Healthy Volunteers | Other | Jan 2027 |
| NCT06212076 | IPG1094 | Phase 1 | Solid Tumor | Oncology | Jul 2027 |
| NCT07508761 | IPG7236 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.